NCT05773586Recruiting
A Study to Investigate the Safety, Pharmacokinetics and Efficacy of APG-5918 in Healthy Subjects or Anemic Patients
A Phase 1 Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalating Study to Evaluate Safety and Tolerability, Pharmacokinetics and Efficacy of APG-5918 in Healthy Subjects or Anemic Patients
Ascentage Pharma Group Inc.Phase 1ClinicalTrials.govdrug
Study focus
- Disease/Condition
- Anemia
- Drug/Device/Intervention
- APG-5918
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Ascentage Pharma Group Inc.
- Location
- Guangzhou, China
Timeline & enrollment
- Phase
- Phase 1
- Start date
- Mar 15, 2023
- End date
- Mar 15, 2026
- Enrollment
- 115 participants
Primary outcome
Treatment-Emergent Adverse Events (TEAEs)
Summary
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics and
 efficacy of APG-5918 in Healthy Subjects or Anemic Patients.
ICD-10 classifications
Anaemia, unspecifiedOther anaemiasOther specified anaemiasIron deficiency anaemiaIron deficiency anaemia, unspecified
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05773586
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT05773586 through Pure Global AI's free database. This Phase 1 trial is sponsored by Ascentage Pharma Group Inc. and is currently Recruiting. The study focuses on Anemia. Target enrollment is 115 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.